Figure 6. The molecular signature of sulforaphane (SFN) action in the obese mice.
(A) The expression of NRF2-target gene Hmox1 in the gastrocnemius skeletal muscle (left panel), and eWAT, inguinal white adipose tissue (iWAT), liver, the hypothalamus (right panel) measured by qPCR of diet-induced obese (DIO) wild-type mice (n = 7 per group) following 1 week of vehicle or 5 mg/kg SFN treatments. *p<0.05, calculated by Student’s t-test. (B) Hmox1 mRNA expression measured by qPCR in the skeletal muscle of DIO NRF2 KO mice (n = 8 per group) following i.p. vehicle or 5 mg/kg SFN treatments. (C, D) RNAseq was conducted on DIO wild-type NRF2 KO mouse tissues following vehicle or SFN treatment (n = 5 per tissue, per treatment). (C) Connectivity Map (CMap) correlation score of the SFN gene expression signature from each tissue. (D) KEGG enrichment pathway analysis of skeletal muscle based on the RNAseq results from WT DIO (left panel) and NRF2 KO DIO (right panel) mice.